TERT and hepatocellular carcinoma: Additionally, early-phase trials of the TERT-encoding DNA vaccine GRANITE-001 have yielded promising results by stimulating T cell responses against telomerase reverse transcriptase (TERT), an antigen prevalent in various cancers, including HCC.